CivicaScript's New Treatment for Neurogenic Orthostatic Hypotension
CivicaScript, a nonprofit organization committed to providing accessible generic medications, has just announced the launch of droxidopa capsules aimed at treating symptomatic neurogenic orthostatic hypotension. This innovative approach seeks to alleviate issues such as dizziness and lightheadedness experienced by individuals, significantly enhancing their quality of life.
Cost-effective Solutions for Patients
The droxidopa capsules will be available for pharmacies at a competitive price of $132 per bottle, which typically contains 90 capsules, offering a month's supply for patients. CivicaScript aims to ensure that the maximum retail price for consumers does not exceed $153, making it a viable option for those on Medicare Part D.
Why Droxidopa Matters
Droxidopa provides essential treatment options for adults facing orthostatic dizziness or the unsettling sensation of impending blackout. CivicaScript's vision is to eliminate excessive costs associated with necessary medications. Their initiative could mean a monthly savings of approximately $2,100 for Medicare Part D patients, which is a substantial reduction compared to current market prices.
Transformative Impact on Healthcare
Brent J. Eberle, President of CivicaScript, emphasizes this launch as a significant milestone for not only patients but also health plans and the entire healthcare ecosystem. The organization stands by its model of collaboration, asserting that disruptive collaboration can transform the way medicines are distributed, making them more affordable and available to all.
Commitment to Transparency and Collaboration
CivicaScript's operational foundation rests on a health care utility model, working alongside trusted manufacturers to ensure the production of low-cost medicines. By collaborating with pharmacies, payers, and pharmacy benefit managers (PBMs), CivicaScript strives to pass on the savings directly to patients while maintaining price transparency throughout the distribution process.
Patient-Centric Approach
Members of CivicaScript identified droxidopa as a priority generic due to its high cost from other manufacturers and significant patient need. The initiative shows that when faced with high drug prices, patients often choose to ration or even forgo essential medications, making this launch even more critical.
About CivicaScript
CivicaScript is dedicated to enhancing drug supply chain transparency, ensuring that everyone has access to quality generic medications at affordable prices. As a nonprofit, its mission revolves around providing essential medicines to promote community health and well-being. They cover over 100 million lives in the United States, making a significant impact on healthcare access.
About Droxidopa
CivicaScript encourages patients to consult with their healthcare providers regarding droxidopa's prescribing information, which is crucial for safe and effective use. For additional details on potential side effects and interactions, you should refer to the Package Insert available through your healthcare provider.
Frequently Asked Questions
What is CivicaScript?
CivicaScript is a nonprofit organization focused on providing affordable generic medications to improve patient health outcomes.
How much will droxidopa cost?
Droxidopa will be available at $132 per bottle, with a maximum retail price of $153 for patients.
Who can benefit from droxidopa?
Droxidopa is specifically designed for adults suffering from symptomatic neurogenic orthostatic hypotension.
What sets CivicaScript apart?
CivicaScript emphasizes transparency and collaborative pricing models in the drug supply chain, ensuring affordability for consumers.
How can patients access CivicaScript products?
Patients can obtain CivicaScript products at participating pharmacies that offer droxidopa capsules.
